These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 7848339)
1. Urinary bladder-selective action of the new antimuscarinic compound vamicamide. Oyasu H; Yamamoto T; Sato N; Sawada T; Ozaki R; Mukai T; Ozaki T; Nishii M; Sato H; Fujiwara T Arzneimittelforschung; 1994 Nov; 44(11):1242-9. PubMed ID: 7848339 [TBL] [Abstract][Full Text] [Related]
2. General pharmacology of the new antimuscarinic compound vamicamide. Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084 [TBL] [Abstract][Full Text] [Related]
3. Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency. Yamamoto T; Koibuchi Y; Miura S; Sawada T; Ozaki R; Esumi K; Ohtsuka M J Urol; 1995 Dec; 154(6):2174-8. PubMed ID: 7500484 [TBL] [Abstract][Full Text] [Related]
4. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity. Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle. Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Kobayashi F; Yageta Y; Yamazaki T; Wakabayashi E; Inoue M; Segawa M; Matsuzawa S Arzneimittelforschung; 2007; 57(3):147-54. PubMed ID: 17469649 [TBL] [Abstract][Full Text] [Related]
9. [Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs]. Nagao M; Kaneko S; Hirota T; Isogai M; Shimizu H Nihon Yakurigaku Zasshi; 1999 Mar; 113(3):157-66. PubMed ID: 10347840 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological effects of solifenacin on human isolated urinary bladder. Masunaga K; Yoshida M; Inadome A; Murakami S; Sugiyama Y; Satoji Y; Maeda Y; Ueda S Pharmacology; 2008; 82(1):43-52. PubMed ID: 18434763 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats. Sugiyama Y; Yoshida M; Masunaga K; Satoji Y; Maeda Y; Nagata T; Inadome A; Ueda S Int J Urol; 2008 Jan; 15(1):76-81. PubMed ID: 18184179 [TBL] [Abstract][Full Text] [Related]